Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
Article
PubMed
Google Scholar
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
Article
PubMed
Google Scholar
Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17(5):1474–81.
Article
PubMed
CAS
Google Scholar
Early Breast Cancer Trialists’ Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.
Article
CAS
Google Scholar
Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, et al. Breast cancer version 3.2014. J Natl Compr Cancer Netw. 2014;12(4):542–90.
Article
CAS
Google Scholar
Obrero M, Yu DV, Shapiro DJ. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J Biol Chem. 2002;277(47):45695–703.
Article
PubMed
CAS
Google Scholar
Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev. 2009;9(9):631–43.
Article
CAS
Google Scholar
Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res. 2004;10(17):5670–6.
Article
PubMed
CAS
Google Scholar
Zhen LL, Zhu X, Zheng W, Wang XY, Wu ZY. Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells. Ai Zheng. 2006;25(7):839–43.
PubMed
CAS
Google Scholar
Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70(5):2085–94.
Article
PubMed
PubMed Central
CAS
Google Scholar
Huber AB, Weinmann O, Brosamle C, Oertle T, Schwab ME. Patterns of Nogo mRNA and protein expression in the developing and adult rat and after CNS lesions. J Neurosci. 2002;22(9):3553–67.
Article
PubMed
CAS
PubMed Central
Google Scholar
Miao RQ, Gao Y, Harrison KD, Prendergast J, Acevedo LM, Yu J, Hu F, Strittmatter SM, Sessa WC. Identification of a receptor necessary for Nogo-B stimulated chemotaxis and morphogenesis of endothelial cells. Proc Natl Acad Sci U S A. 2006;103(29):10997–1002.
Article
PubMed
PubMed Central
CAS
Google Scholar
Rana U, Liu Z, Kumar SN, Zhao B, Hu W, Bordas M, Cossette S, Szabo S, Foeckler J, Weiler H, et al. Nogo-B receptor deficiency causes cerebral vasculature defects during embryonic development in mice. Dev Biol. 2016;410(2):190–201.
Article
PubMed
CAS
Google Scholar
Park EJ, Grabinska KA, Guan Z, Sessa WC. NgBR is essential for endothelial cell glycosylation and vascular development. EMBO Rep. 2016;17(2):167–77.
Article
PubMed
PubMed Central
CAS
Google Scholar
Zhao B, Hu W, Kumar S, Gonyo P, Rana U, Liu Z, Wang B, Duong WQ, Yang Z, Williams CL, et al. The Nogo-B receptor promotes Ras plasma membrane localization and activation. Oncogene. 2017;36(24):3406–16.
Article
PubMed
PubMed Central
CAS
Google Scholar
Wang B, Zhao B, North P, Kong A, Huang J, Miao QR. Expression of NgBR is highly associated with estrogen receptor alpha and survivin in breast cancer. PLoS One. 2013;8(11):e78083.
Article
PubMed
PubMed Central
CAS
Google Scholar
Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58(23):5315–20.
PubMed
CAS
Google Scholar
Zhao B, Xu B, Hu W, Song C, Wang F, Liu Z, Ye M, Zou H, Miao QR. Comprehensive proteome quantification reveals NgBR as a new regulator for epithelial-mesenchymal transition of breast tumor cells. J Proteome. 2015;112:38–52.
Article
CAS
Google Scholar
Wang L, Zhang X, Wang ZY. The Wilms’ tumor suppressor WT1 regulates expression of members of the epidermal growth factor receptor (EGFR) and estrogen receptor in acquired tamoxifen resistance. Anticancer Res. 2010;30(9):3637–42.
PubMed
PubMed Central
CAS
Google Scholar
Luo J, Wang W, Tang Y, Zhou D, Gao Y, Zhang Q, Zhou X, Zhu H, Xing L, Yu J. mRNA and methylation profiling of radioresistant esophageal cancer cells: the involvement of Sall2 in acquired aggressive phenotypes. J Cancer. 2017;8(4):646–56.
Article
PubMed
PubMed Central
CAS
Google Scholar
Yuan J, Liu M, Yang L, Tu G, Zhu Q, Chen M, Cheng H, Luo H, Fu W, Li Z, et al. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and beta1-integrin signaling pathway in tumor cells. Breast Cancer Res. 2015;17:69.
Article
PubMed
PubMed Central
CAS
Google Scholar
Thewes V, Simon R, Schroeter P, Schlotter M, Anzeneder T, Buttner R, Benes V, Sauter G, Burwinkel B, Nicholson RI, et al. Reprogramming of the ERRalpha and ERalpha target gene landscape triggers tamoxifen resistance in breast cancer. Cancer Res. 2015;75(4):720–31.
Article
PubMed
CAS
Google Scholar
Jin Y, Hu W, Liu T, Rana U, Aguilera-Barrantes I, Kong A, Kumar SN, Wang B, Gao P, Wang X, et al. Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel. Cancer Lett. 2018;419:233–44.
Article
PubMed
CAS
PubMed Central
Google Scholar
de Leeuw R, Neefjes J, Michalides R. A role for estrogen receptor phosphorylation in the resistance to tamoxifen. Int J Breast Cancer. 2011;2011:232435.
Article
PubMed
PubMed Central
CAS
Google Scholar
Anbalagan M, Rowan BG. Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer. Mol Cell Endocrinol. 2015;418(Pt 3):264–72.
Article
PubMed
CAS
Google Scholar
Dai X, Cai C, Xiao F, Xiong Y, Huang Y, Zhang Q, Xiang Q, Lou G, Lian M, Su Z, et al. Identification of a novel aFGF-binding peptide with anti-tumor effect on breast cancer from phage display library. Biochem Biophys Res Commun. 2014;445(4):795–801.
Article
PubMed
CAS
Google Scholar
Higuchi T, Endo M, Hanamura T, Gohno T, Niwa T, Yamaguchi Y, Horiguchi J, Hayashi S. Contribution of Estrone sulfate to cell proliferation in aromatase inhibitor (AI) -resistant, Hormone Receptor-Positive Breast Cancer. PloS One. 2016;11(5):e0155844.
Article
PubMed
PubMed Central
CAS
Google Scholar
Paoletti C, Larios JM, Muniz MC, Aung K, Cannell EM, Darga EP, Kidwell KM, Thomas DG, Tokudome N, Brown ME, et al. Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance. Mol Oncol. 2016;10(7):1078–85.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kim J, Lee J, Jang SY, Kim C, Choi Y, Kim A. Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines. Oncol Rep. 2016;35(5):2553–60.
Article
PubMed
PubMed Central
CAS
Google Scholar
Fan P, Agboke FA, Cunliffe HE, Ramos P, Jordan VC. A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer. Eur J Cancer. 2014;50(16):2866–76.
Article
PubMed
PubMed Central
CAS
Google Scholar
Fan W, Chang J, Fu P. Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. Future Med Chem. 2015;7(12):1511–9.
Article
PubMed
PubMed Central
CAS
Google Scholar
Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer–an overview and update. Mol Cell Endocrinol. 2015;418(Pt 3):220–34.
Article
PubMed
PubMed Central
CAS
Google Scholar
Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 2004;10(1 Pt 2):331S–6S.
Article
PubMed
CAS
Google Scholar
Xiong J, Su T, Qu Z, Yang Q, Wang Y, Li J, Zhou S. Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer. Oncotarget. 2016;7(17):23933–46.
Article
PubMed
PubMed Central
Google Scholar
Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A. 2001;98(20):11598–603.
Article
PubMed
PubMed Central
CAS
Google Scholar
Dong C, Zhao B, Long F, Liu Y, Liu Z, Li S, Yang X, Sun D, Wang H, Liu Q, et al. Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein. Oncotarget. 2016;7(8):8850–65.
Article
PubMed
PubMed Central
Google Scholar
Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25(3):304–17.
Article
PubMed
PubMed Central
CAS
Google Scholar
Bailey ST, Shin H, Westerling T, Liu XS, Brown M. Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc Natl Acad Sci U S A. 2012;109(44):18060–5.
Article
PubMed
PubMed Central
Google Scholar
Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 2002;21(17):2613–22.
Article
PubMed
CAS
Google Scholar
Span PN, Tjan-Heijnen VC, Manders P, van Tienoven D, Lehr J, Sweep FC. High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer. Breast Cancer Res Treat. 2006;98(2):223–30.
Article
PubMed
CAS
Google Scholar
Omerovic J, Laude AJ, Prior IA. Ras proteins: paradigms for compartmentalised and isoform-specific signalling. Cell Mol Life Sci. 2007;64(19–20):2575–89.
Article
PubMed
PubMed Central
CAS
Google Scholar
Hancock JF. Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol. 2003;4(5):373–84.
Article
PubMed
CAS
Google Scholar
Buday L, Downward J. Many faces of Ras activation. Biochim Biophys Acta. 2008;1786(2):178–87.
PubMed
CAS
Google Scholar
McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzym Regul. 2006;46:249–79.
Article
CAS
Google Scholar
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263–84.
Article
PubMed
CAS
Google Scholar
Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008;9(7):517–31.
Article
PubMed
PubMed Central
CAS
Google Scholar
Acconcia F, Kumar R. Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett. 2006;238(1):1–14.
Article
PubMed
CAS
Google Scholar
Zhang D, Trudeau VL. Integration of membrane and nuclear estrogen receptor signaling. Comp Biochem Physiol A Mol Integr Physiol. 2006;144(3):306–15.
Article
PubMed
CAS
Google Scholar
Soltysik K, Czekaj P. Membrane estrogen receptors - is it an alternative way of estrogen action? J Physiol Pharmacol. 2013;64(2):129–42.
PubMed
CAS
Google Scholar
Pritchard JE, Dillon PM, Conaway MR, Silva CM, Parsons SJ. A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model. Oncology. 2012;83(6):305–20.
Article
PubMed
CAS
Google Scholar
Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996;15(9):2174–83.
Article
PubMed
PubMed Central
CAS
Google Scholar
Guo S, Li Y, Tong Q, Gu F, Zhu T, Fu L, Yang S. deltaEF1 down-regulates ER-alpha expression and confers tamoxifen resistance in breast cancer. PLoS One. 2012;7(12):e52380.
Article
PubMed
PubMed Central
CAS
Google Scholar
Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology. 2003;144(3):1032–44.
Article
PubMed
CAS
Google Scholar
Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol. 2001;15(8):1344–59.
PubMed
CAS
Google Scholar
Bayliss J, Hilger A, Vishnu P, Diehl K, El-Ashry D. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin Cancer Res. 2007;13(23):7029–36.
Article
PubMed
CAS
Google Scholar